Kirschbaum Mark 4
4 · Cyclacel Pharmaceuticals, Inc. · Filed Jul 3, 2023
Insider Transaction Report
Form 4
Kirschbaum Mark
Chief Medical Officer
Transactions
- Award
Stock Option (right to buy)
2023-06-30+70,200→ 70,200 totalExercise: $0.59From: 2026-06-30Exp: 2033-06-30→ Common Stock (70,200 underlying)
Footnotes (1)
- [F1]The reporting person received an award of 70,200 options on June 30, 2023, which shall vest in full on June 30, 2026, provided, however, that if certain clinical milestones are achieved then such options shall vest in full earlier in connection with such achievement.